Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Executives Outline Expansion Plans at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

Global expansions highlighted
This year’s DCAT Member Company Announcement Forum, which was held on March 21, 2022, kicked off DCAT Week 2022 with CEOs and senior executives highlighting major news announcements from their companies with developments across the global bio/pharmaceutical manufacturing value chain. DCAT Week, held March 21–24, 2022, is the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing.

Expansions in biomanufacturing (drug substance), both traditional biologics and new modalities, such as cell and gene therapies, including select investments in mRNA manufacturing, were a major area of focus of several companies’ announcements, with certain companies highlighting billion-dollar plus expansion plans.

So which companies are making the news in biomanufacturing? On the CDMO side, Thermo Fisher Scientific, Samsung Biologics, Lonza, Catalent, AGC Biologics, and IDT Biologika are moving forward with key expansions in biologics, as is Cytiva, the former Biopharma business of GE Life Sciences, now part of Danaher Corporation, and a large supplier of products supporting bioprocessing.

Several of these CDMOs with integrated capabilities in biologic drug substance and drug-product manufacturing also provided updates on their expansions in fill–finish/sterile drug-product development and manufacturing (Thermo Fisher Scientific, Lonza, Catalent, and IDT Biologika) as did Selkirk Pharma, a CDMO of injectable products.

Also on the drug-product side, Catalent highlighted the integration of its $1-billion acquisition of Bettera, providing it with innovative dose technologies for consumer healthcare products.  CordenPharma outlined the acquisition of three drug-product manufacturing facilities to expand its capacity for oral dosage forms and other dosage forms (sachets, non-sterile liquids).

On the small-molecule drug substance side, several companies announced expansions. WuXi STA is proceeding with a major expansion plan in its global R&D and manufacturing network for small-molecule APIs, including high-potency APIs, as well as for oligonucleotides, peptides, and their conjugates in addition to investments in flow chemistry and biocatalysis. HAS Healthcare Advanced Healthcare Systems (formerly Helsinn Advanced Synthesis) is progressing a multi-year expansion plan, and Cambrex announced a $100-million expansion in small-molecule API development and manufacturing.

Details of all these announcements, including investment amounts, capacity additions, and timelines for completion/start-up are outlined in the new stories below.  Plus, other DCAT Member Companies are making the news: watch for the upcoming April 8th issue of DCAT Value Chain Insights for highlights.

Recent Feature Articles

Tariffs & Pharmaceuticals: US Government Takes the Next Step

By
The US Secretary of Commerce has initiated an investigation to determine the effects on US national security of imports of pharmaceuticals, including finished drug products, active pharmaceutical ingredients (APIs), and key starting materials, potentially paving the way for pharmaceutical industry-specific tariffs.

Small-Molecules’ Gain: Trump Signs Executive Order on Drug Pricing

By
President Donald Trump has signed an Executive Order on drug pricing, which calls for eliminating the so-called “pill penalty” under the Medicare Prescription Drug Negotiation Program to equalize the post-approval time frame for drugs subject to negotiation for small-molecule drugs and biologics.

Unpacking the Latest on Pharma, Trade & Tariffs: What May Be Next?

By
Global volatility on the trade front continued this week as the US put a 90-day pause on implementing its plan for reciprocal tariffs on a country-by-country basis, but uncertainty remains, particularly for certain trading partners, notably China. What is the impact on the pharma industry and what may in store.   

Pharma CEOs Speak on the Fallout from Evolving US–EU Trade Policy

By
The European Federation of Pharmaceutical Industries and Associations, representing innovator drug companies in Europe, and Medicines for Europe, representing generics and biosimilars producers in Europe, speak out on  the impact of a changing tariff scheme on the bio/pharma industry in the EU and propose action plans.